Nurix Therapeutics (NRIX) News Today $21.18 +0.37 (+1.78%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period 350,640 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Lord Abbett & CO. LLCLord Abbett & CO. LLC acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 350,640 shares of the company's stock, valued at approximately $7,879,000. Lord AbbettDecember 17 at 5:19 AM | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and sixteen have isDecember 17 at 2:38 AM | marketbeat.comBuy Rating Reaffirmed for Nurix Therapeutics: Promising Clinical Data and Increased Approval Probability for NX-5948December 12, 2024 | markets.businessinsider.comFmr LLC Purchases 511,256 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)Fmr LLC lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 675.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 586,902 shares of the company's stock after acquiring anDecember 12, 2024 | marketbeat.comIs Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?December 11, 2024 | finance.yahoo.comNurix Therapeutics (NRIX) Receives a Buy from Stifel NicolausDecember 11, 2024 | markets.businessinsider.comBTIG Initiates Coverage of Nurix Therapeutics (NRIX) with Buy RecommendationDecember 11, 2024 | msn.comNurix Therapeutics (NRIX) Receives a Buy from BarclaysDecember 11, 2024 | markets.businessinsider.comHC Wainwright Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock PriceHC Wainwright boosted their price objective on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday.December 11, 2024 | marketbeat.comWellington Management Group LLP Raises Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Wellington Management Group LLP increased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 8.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,482,105 shares of the company's stock after purchasing an adDecember 11, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at BTIG ResearchBTIG Research started coverage on shares of Nurix Therapeutics in a research report on Tuesday. They set a "buy" rating and a $35.00 price objective on the stock.December 10, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX)Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Nurix Therapeutics in a research note on Tuesday.December 10, 2024 | marketbeat.comNurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual MeetingDecember 9, 2024 | globenewswire.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Position Trimmed by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. trimmed its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 17.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 511,720 shares of the compaDecember 9, 2024 | marketbeat.com27,000 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 27,000 shares of the company's stock, valueDecember 7, 2024 | marketbeat.comDecoding 9 Analyst Evaluations For Nurix TherapeuticsDecember 6, 2024 | benzinga.comBMO Capital Initiates Coverage of Nurix Therapeutics (NRIX) with Outperform RecommendationDecember 6, 2024 | msn.comNurix Therapeutics (NASDAQ:NRIX) Shares Up 8.3% - What's Next?Nurix Therapeutics (NASDAQ:NRIX) Trading 8.3% Higher - Still a Buy?December 6, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Earns Outperform Rating from Analysts at BMO Capital MarketsBMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research note on Friday. They issued an "outperform" rating and a $35.00 price target on the stock.December 6, 2024 | marketbeat.comNurix Therapeutics initiated with an Outperform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comWhy Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 5, 2024 | msn.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Redmile Group LLCRedmile Group LLC cut its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,280,981 shares of the company's stock after selliDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Sells 35,708 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)Parkman Healthcare Partners LLC reduced its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 7.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 438,971 shares of the company's stoDecember 4, 2024 | marketbeat.comPatient Square Capital LP Purchases Shares of 325,789 Nurix Therapeutics, Inc. (NASDAQ:NRIX)Patient Square Capital LP acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 325,789 sharesDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Acquires Shares of 105,228 Nurix Therapeutics, Inc. (NASDAQ:NRIX)Cinctive Capital Management LP bought a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 105,228 shares of the company's stock, valued at approximately $2,364,0December 3, 2024 | marketbeat.comNurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual MeetingDecember 2, 2024 | globenewswire.comWasatch Advisors LP Decreases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Wasatch Advisors LP lowered its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 17.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 708,377 shares of the company's stock after selling 149,690 shares during the quarter. WasatDecember 1, 2024 | marketbeat.comFred Alger Management LLC Acquires 127,948 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)Fred Alger Management LLC raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 336.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 166,014 shares of the company's stock after acquiring an additionDecember 1, 2024 | marketbeat.comDynamic Technology Lab Private Ltd Invests $530,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Dynamic Technology Lab Private Ltd bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 23,578 shares of the company's stock, valued at approximately $530,000. Several other hedge fNovember 30, 2024 | marketbeat.comVestal Point Capital LP Decreases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Vestal Point Capital LP decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 15.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 425,000 shares of the compaNovember 29, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Sells 28,756 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)Massachusetts Financial Services Co. MA reduced its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 29.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,415 shares of the companyNovember 28, 2024 | marketbeat.comNurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | globenewswire.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from AnalystsNurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating onNovember 22, 2024 | marketbeat.comNurix Therapeutics announces PRIME designation for NX-5948 from EMANovember 21, 2024 | markets.businessinsider.comNurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic LeukemiaNovember 20, 2024 | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Shares Gap Down - Here's WhyNurix Therapeutics (NASDAQ:NRIX) Shares Gap Down - Time to Sell?November 18, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Acquires New Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 553,251 shares of the company's stockNovember 18, 2024 | marketbeat.comNurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024November 17, 2024 | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Shares Down 8.7% - Should You Sell?Nurix Therapeutics (NASDAQ:NRIX) Trading Down 8.7% - Here's WhyNovember 15, 2024 | marketbeat.comARK Investment Management LLC Sells 106,967 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)ARK Investment Management LLC lowered its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,216,365 shares ofNovember 8, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Hits New 52-Week High - Here's WhyNurix Therapeutics (NASDAQ:NRIX) Sets New 12-Month High - Should You Buy?November 7, 2024 | marketbeat.comPromising Efficacy and Safety of Nurix Therapeutics’ NX-5948 Justifies Buy RatingNovember 7, 2024 | markets.businessinsider.comNurix Therapeutics' (NRIX) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday.November 6, 2024 | marketbeat.comNurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | finance.yahoo.comNurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $86,096.88 in StockNovember 2, 2024 | insidertrades.comHoute Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) StockNurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 3,546 shares of the company's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $818,818.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.November 1, 2024 | marketbeat.comTracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 UpdateNovember 1, 2024 | seekingalpha.comNurix Therapeutics to Participate in Upcoming Investor ConferencesOctober 31, 2024 | globenewswire.comInsider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells 2,368 Shares of StockOctober 31, 2024 | insidertrades.comAllspring Global Investments Holdings LLC Makes New $3.15 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX)Allspring Global Investments Holdings LLC acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 140,273 shares of the company's stock, valued at approximatOctober 30, 2024 | marketbeat.com Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now NRIX Media Mentions By Week NRIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRIX News Sentiment▼0.720.71▲Average Medical News Sentiment NRIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRIX Articles This Week▼115▲NRIX Articles Average Week Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ELAN News CYTK News TGTX News VKTX News BBIO News CRNX News KRYS News ACLX News ADMA News RARE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRIX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRIX Stock Alerts